AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first
AstraZeneca and Daiichi Sankyo's Enhertu, combined with pertuzumab, received EU approval for treating HER2-positive metastatic breast cancer. The approval follows positive trial results showing a 44% reduction in disease progression risk and a median PFS of 40.7 months. AstraZeneca will pay Daiichi Sankyo $100m for this indication.
How this was made
The 30-second read
Why it matters
This is a regulatory label expansion into first-line, supported by a large PFS separation versus THP (40.7 vs 26.9 months) and a stated milestone payment linkage between AstraZeneca and Daiichi Sankyo.
Market read
Traders can use the approval as a catalyst for repricing Enhertu’s EU first-line revenue potential and the co-developers’ oncology pipeline value.
What to watch
The article does not address EU launch timing, reimbursement status, or competitive responses from other HER2 regimens, which can materially affect near-term sales realization.
Background
The European Commission approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer, following a positive EMA CHMP opinion and DESTINY-Breast09 phase 3 results.
Ticker impact
AstraZeneca’s Enhertu plus pertuzumab received first-line EU approval for HER2-positive metastatic breast cancer, expanding the drug’s labeled use.
Near-term upside bias as investors price in broader EU uptake and potential faster sequencing into first-line regimens.
The article is a direct regulatory approval for a major oncology asset, with efficacy benchmarks (PFS 40.7 vs 26.9 months) and a stated AstraZeneca milestone payment tied to the indication.
Market effects
Strengthens the HER2 metastatic breast cancer competitive landscape and may increase investor focus on antibody-drug conjugate (ADC) first-line sequencing in oncology.
Positive read-through for EU oncology prescribing and payer coverage expectations for HER2-positive metastatic breast cancer.
Supports global commercialization momentum for Enhertu and can influence how investors model future label expansions in other regions.
Counterpoint
EU approval does not guarantee immediate uptake; pricing, reimbursement, and physician adoption curves could delay revenue impact versus trial-driven optimism.
Key entities
- drugEnhertu (trastuzumab deruxtecan)
ADC used in combination with pertuzumab for first-line HER2-positive metastatic breast cancer in the EU.
- companyAstraZeneca
Co-developer and commercial partner receiving the EU approval impact and paying/receiving milestone economics per the article.
- companyDaiichi Sankyo
Co-developer of Enhertu, due to receive a $100m milestone payment tied to this first-line EU indication.
- regulatorEuropean Commission
Approved the indication in the EU after EMA CHMP positive opinion.
- clinical trialDESTINY-Breast09
Phase 3 trial underpinning the approval, reporting PFS benefit versus THP.
